Chamblin v. K-Mart Corp., A04A2203.
| Decision Date | 17 March 2005 |
| Docket Number | No. A04A2203.,A04A2203. |
| Citation | 272 Ga. App. 240,612 S.E.2d 25 |
| Parties | CHAMBLIN et al. v. K-MART CORPORATION. |
| Court | Georgia Court of Appeals |
Stephen Ivie, Ashburn, John Brown, Augusta, for Appellants.
Nicole Stout, James Strawinski, Strawinski & Goldberg, Atlanta, for Appellee.
Jimmy and Jan Chamblin filed the underlying action against K-Mart Corporation ("K-Mart") after Jan Chamblin had an extreme allergic reaction to a prescription filled at a K-Mart pharmacy.1 Jan Chamblin alleged that the pharmacist failed to warn her of the potential side effects of the drug in violation of the appropriate standard of care. The trial court granted summary judgment to K-Mart based on its conclusion that the "learned intermediary" doctrine barred any recovery against the pharmacy. The trial court denied the Chamblins' motion for partial summary judgment on the issue of K-Mart's negligence per se. The Chamblins appeal, arguing that the trial court erred in granting K-Mart's motion and in denying their motion. We affirm the judgment of the trial court.
Summary judgment is proper when there is no genuine issue of material fact and the movant is entitled to judgment as a matter of law. OCGA § 9-11-56(c). A de novo standard of review applies to an appeal from a grant of summary judgment, and we view the evidence, and all reasonable conclusions and inferences drawn from it, in the light most favorable to the nonmovant.
(Citation omitted.) Matjoulis v. Integon Gen. Ins. Corp., 226 Ga.App. 459(1), 486 S.E.2d 684 (1997).
So viewed, the record shows that on December 20, 1995, Jan Chamblin was given two sample bottles of Daypro, which is an "NSAID" or nonsteroidal anti-inflammatory drug, by her orthopedic surgeon, Dr. Aguero, after she complained of knee and shoulder pain. The sample bottles each contained 14 caplets of Daypro. According to Chamblin, the doctor did not explain any potential side effects of the drug, and she did not inquire about any such effects. Chamblin took one sample caplet of Daypro on December 20, and two caplets each day for the next twelve days.
According to Chamblin, on or about December 27, 1995, she began experiencing headaches, "dry and itchy" eyes, and flu-like symptoms. She had an appointment with Dr. Aguero on December 29, but she did not mention her symptoms. Dr. Aguero gave Chamblin a prescription for Daypro. Chamblin continued taking the samples of Daypro through January 1, 1996. The next day, she had the prescription filled at the K-Mart pharmacy. Chamblin deposed that she did not have any questions or concerns at the time she picked up her prescription and that she did not ask to speak with the pharmacist. Daniel Brock, the K-Mart pharmacist who filled the prescription, deposed that it was his usual practice to counsel all of his customers; however, he had no specific recollection of Chamblin. He further testified that a drug synopsis is attached to the bag of every prescription dispensed by the K-Mart pharmacy.
According to Chamblin, on January 3, 1996, she developed blisters in her mouth and experienced difficulty breathing. She went to the emergency room at South Georgia Medical Center and then to Dr. Leon Smith, who diagnosed her as having a reaction to the Daypro known as Stevens-Johnson syndrome, which is a rare extreme allergic reaction to medication. Chamblin was treated at Shands Hospital at the University of Florida.
Chamblin's own expert witness, orthopedic surgeon Dr. Lazaro Guerra,2 admitted that "probably any drug could cause Stevens-Johnson syndrome." Dr. Guerra also testified that Daypro has less than a one in one million chance of causing Stevens-Johnson syndrome and that he does not warn his own patients about that potential reaction when he prescribes the drug. He further testified that there was no reason for Dr. Aguero to foresee the rare occurrence of Stevens-Johnson in Chamblin's case. Additionally, Dr. Guerra deposed that there was no way of determining whether the onset of Stevens-Johnson syndrome was caused by the sample caplets of Daypro provided by Dr. Aguero or by the prescription dispensed by K-Mart.
The Chamblins' sole theory of recovery against K-Mart is that it failed to warn Jan Chamblin of the potential side effects of Daypro, including Stevens-Johnson syndrome, in violation of the standard of care for pharmacists. There is no allegation that the K-Mart pharmacist improperly filled the prescription, provided Chamblin with incorrect instructions, or gave the drug in an incorrect strength or quantity.
1. In its grant of summary judgment to K-Mart on the issue of negligence, the trial court concluded that "the `learned intermediary rule' ... places the duty to counsel or warn patients about the possible adverse effects of prescribed medications upon the prescribing physician and not upon the pharmacist filling said prescription." The Chamblins contend that the court erred in reaching this conclusion. We affirm the judgment of the trial court on this ground.
To state a cause of action for negligence in Georgia, a plaintiff must show "(1) [a] legal duty to conform to a standard of conduct raised by the law for the protection of others against unreasonable risks of harm; (2) a breach of this standard; (3) a legally attributable causal connection between the conduct and the resulting injury; and (4) some loss or damage ... as a result of the alleged breach." Bradley Center v. Wessner, 250 Ga. 199, 200(1), 296 S.E.2d 693 (1982). In this case, the Chamblins argue that the K-Mart pharmacy owed Jan Chamblin a duty to warn her of any potential adverse effects of Daypro based on the regulations of the Georgia State Board of Pharmacy (the "Board") requiring dispensing pharmacists to offer to counsel patients about their medication. See Ga. Comp. R. & Regs. r. 480-31-.01(c)(1). They further argue that the K-Mart pharmacist breached this duty by failing to warn Chamblin of the risk of Stevens-Johnson syndrome.
Significantly, the rules promulgated by the Board do not establish a duty to warn about every possible side effect of a drug. Ga. Comp. R. & Regs. r. 480-31-.01(c)(1) provides:
Upon receipt of a Prescription Drug Order and following a review of the patient's record, the dispensing Pharmacist shall personally offer to discuss matters which will enhance or optimize drug therapy with each patient.... Such discussion... shall include appropriate elements of patient counseling, based on the professional judgment of the pharmacist. Such elements may include but are not limited to the following:... (v) common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered....
While the rule requires that counseling be offered to a customer, the topics of discussion are determined entirely by the subjective judgment of the individual pharmacist, and the rule only refers to common side or adverse effects in its list of elements of discussion that may be included. We cannot conclude that this rule established a heightened duty on the part of the K-Mart pharmacist to advise Chamblin of every remote potential side effect of Daypro.
This Court adopted the "learned intermediary" rule in Walker v. Jack Eckerd Corp., 209 Ga.App. 517, 434 S.E.2d 63 (1993), after an exhaustive discussion of the rule's application in numerous other jurisdictions. Id. at 522-523(2), 434 S.E.2d 63. In that case, we announced the rule as follows:
A pharmacist owes the customer the highest degree of prudence, thoughtfulness, and diligence. However, a pharmacist has no duty to warn the customer or notify the physician that the drug is being prescribed in dangerous amounts, that the customer is being over medicated, or that the various drugs in their prescribed quantities could cause adverse reactions to the customer. It is the duty of the prescribing physician to know the characteristics of the drug he is prescribing, to know how much of the drug he can give his patient, to elicit from the patient what other drugs the patient is taking, to properly prescribe various combinations of drugs, to warn the patient of any dangers associated with taking the drug, to monitor the patient's dependence on the drug, and to tell the patient when and how to take the drug. Further, it is the duty of the patient to...
To continue reading
Request your trial
-
Roberts v. Quick RX Drugs, Inc.
...the Quick Rx employees failed to make the requisite offer. The record is simply silent on that point. See Chamblin v. K–Mart Corp., 272 Ga. App. 240, 244 (1), 612 S.E.2d 25 (2005) (summary judgment for pharmacy affirmed on claim of breach of duty to warn/offer counseling where record contai......
-
Allen v. United States
...law duty to inform patients of the material risks of a proposed treatment or procedure." (citations omitted)); Chamblin v. K-Mart Corp., 612 S.E.2d 25, 28 (Ga. Ct. App. 2005) ("The Court's reasoning that the treating physician is in a better position to warn a patient of the dangers associa......
-
Coney v. Mylan Pharmaceuticals, Inc.
...have no duty to warn consumers of risks associated with prescription drugs under the learned intermediary rule. See Chamblin v. K-Mart Corp., 272 Ga. App. 240, 244 (2005). In Chamblin, the court held that the prescribing physician "is in a better position to warn the patient." See id. Accor......
-
Nail v. State
...knowledge of a patient's particular need and susceptibilities. (Citation and punctuation omitted.) Chamblin v. K-Mart Corp., 272 Ga.App. 240, 243-244(1), 612 S.E.2d 25 (2005).2 Because a physician's warning of potential risks or side effects of prescription medications involves a profession......
-
Product Liability - Franklin P. Brannen, Jr., Richard L. Sizemore, and Jacob E. Daly
...605 S.E.2d at 388-90. 74. Id. at 892-93, 605 S.E.2d at 387. 75. Id. at 894, 605 S.E.2d at 388. 76. Id. at 897, 605 S.E.2d at 390. 77. 272 Ga. App. 240, 612 S.E.2d 25 (2005). 78. Id. at 242, 612 S.E.2d at 27. 79. Id. at 240-42, 612 S.E.2d at 26-27. 80. Id. at 245, 612 S.E.2d at 29. 81. Id. a......
-
Product Liability
...333, 335-36 (2007).189. McCombs v. Synthes (U.S.A.), 277 Ga. 252, 253, 587 S.E.2d 594, 595 (2003).190. Id.191. Chamblin v. K-Mart Corp., 272 Ga. App. 240, 243-44, 612 S.E.2d 25, 27-29 (2005).192. Catlett v. Wyeth, Inc., 379 F. Supp. 2d 1374, 1381 (M.D. Ga. 2004).193. McCombs, 277 Ga. at 253......